HUMA (Humacyte) Notes Receivable: $0.00 Mil (As of Mar. 2026)


HUMA Humacyte Inc HUMA
23 GF Score
Price $0.71
! 6 Warning Signs
View Full Analysis

What is Humacyte Notes Receivable?

Humacyte HUMA +5.19% 23 Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus rates HUMA with a GF Score™ of 23/100. The stock has 6 warning signs investors should review.

Humacyte's Notes Receivable for the quarter that ended in Mar. 2026 was $0.00 Mil.

Humacyte Notes Receivable Historical Data

* Premium members only.

The historical data trend for Humacyte's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Humacyte Notes Receivable Chart

Humacyte Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Humacyte Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HUMA
23GF Score
Humacyte Inc HUMA
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Humacyte Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Humacyte (HUMA) has a Notes Receivable of $0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Humacyte and its competitors.
Is Humacyte's Notes Receivable too high?
Humacyte's current Notes Receivable is $0.00 Mil. Overall, Humacyte has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Humacyte's Notes Receivable compare to ORMP and EQ?
Humacyte's Notes Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Humacyte and its competitors. Humacyte's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Humacyte stock overvalued right now?
Humacyte (HUMA) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Humacyte's overall GF Score™ is 23/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Humacyte (HUMA), the current Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Humacyte Business Description

Address 2525 East North Carolina Highway 54, Durham, NC, USA, 27713
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
23GF Score

Get the complete analysis for HUMA

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.71
Price